



STANDARD COMMERCIAL AND NSA DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

LENACAPAVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LENACAPAVIR SODIUM	SUNLENCA	48555		GPI-10 (1210155520)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of human immunodeficiency virus type 1 (HIV-1) and meet **ALL** of the following criteria?
 - The patient is 18 years of age or older
 - The patient is treatment-experienced
 - The patient's HIV-1 is multidrug resistant and has failed current antiretroviral regimen due to resistance, intolerance, or safety considerations

If yes, **approve for 12 months by GPID or GPI-14 for all dosage forms as follows:**

- **300mg tablet: #5 per 6 months.**
- **463.5mg/1.5mL vial: #3 mL per 6 months.**

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **LENACAPAVIR (Sunlenca)** requires the following rule(s) be met for approval:

- A. You have human immunodeficiency virus type 1 (HIV-1: a type of immune disorder)
- B. You are 18 years of age or older
- C. You are treatment-experienced
- D. You have a multidrug resistant (not responding to treatment) HIV-1 infection and have failed your current antiretroviral regimen (HIV treatment) due to resistance, intolerance (side effects), or safety considerations

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL AND NSA DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

LENACAPAVIR

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Sunlenca.

REFERENCES

- Sunlenca [Prescribing Information]. Foster City, CA: Gilead Sciences, Inc.; December 2022.

Library	Commercial	NSA
Yes	Yes	Yes

Part D Effective: N/A

Commercial Effective: 06/01/23

Created: 01/23

Client Approval: 05/23

P&T Approval: 01/22